Evidence map›Paper›PMID 25261571›Full record

ReviewJournal of neurology, neurosurgery, and psychiatry2014

Biomarkers in dementia: clinical utility and new directions.

R M Ahmed, R W Paterson, J D Warren, H Zetterberg, J T O'Brien, N C Fox, G M Halliday, J M Schott

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of neurology, neurosurgery, and psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 5 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 5 syntheses or guidelines pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Blood DNA methylation as a potential biomarker of dementia: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018
    Pooled it
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review.International journal of molecular sciences · 2024
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

R M AhmedNeuroscience Research Australia and the University of NSW, Sydney, New South Wales, Australia.
R W PatersonDementia Research Centre, University College London Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
J D WarrenDementia Research Centre, University College London Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
H ZetterbergDepartment of Molecular Neuroscience, University College London Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Institute of Neuroscience and Physiology, Mölndal, Sweden.
J T O'BrienDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
N C FoxDementia Research Centre, University College London Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
G M HallidayNeuroscience Research Australia and the University of NSW, Sydney, New South Wales, Australia.
J M SchottDementia Research Centre, University College London Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
National Hospital for Neurology and Neurosurgery · GBNeuroscience Research Australia · AUUniversity College London · GBUniversity of Cambridge · GBUniversity of Gothenburg · SE

Funding

Wellcome Trust 091673
6 · The paper itself

Abstract

Imaging, cerebrospinal fluid (CSF) and blood-based biomarkers have the potential to improve the accuracy by which specific causes of dementia can be diagnosed in vivo, provide insights into the underlying pathophysiology, and may be used as inclusion criteria and outcome measures for clinical trials. While a number of imaging and CSF biomarkers are currently used for each of these purposes, this is an evolving field, with numerous potential biomarkers in varying stages of research and development. We review the currently available biomarkers for the three most common forms of neurodegenerative dementia, and give an overview of research techniques that may in due course make their way into the clinic.

Indexed as

BiomarkersBrainDementiaFunctional NeuroimagingHumansNeuroimagingBiomarkersALZHEIMER'S DISEASEBRAIN MAPPINGCOGNITIONDEMENTIAFRONTAL LOBE

Identifiers

PMID25261571
PMCPMC4335455
OpenAlexW2047462352

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.